PR Newswire Clinical TrialsOriginal article
Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026
ConferenceATNM-400Positive
AI Analysis
Summary
Actinium Pharmaceuticals is presenting first-in-human Phase 1 data for ATNM-400 in metastatic castration-resistant prostate cancer and preclinical data in KRAS- and ALK-driven NSCLC at EANM 2026. The company positions ATNM-400 as a differentiated approach beyond PSMA with pan-tumor potential.
Clinical Trial Data
Phase
Phase 1
Outcome Details
First-in-human Phase 1 clinical data in mCRPC and preclinical lung cancer data presented at EANM 2026; no results detailed in the available text.
Importance:5/10
Sentiment:
0.30
ATNM-400EANM 2026prostate cancermCRPCnon-small cell lung cancerKRASALKradiopharmaceuticalfirst-in-humanPhase 1
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 19, 2026 11:30 AM